Paracetamol 500 mg Film Coated Tablets clinical trials
3 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
A 12-month, randomized, single-blind, placebo-controlled exposure-response study of TCD601 (siplizumab) in new onset type 1 diabetes patients (STRIDE)
This study is looking into a new treatment for people newly diagnosed with type 1 diabetes. It compares a drug called TCD601 (siplizumab) with a dummy treatment (placebo) over 12 months to see if it can help the body keep making its own insulin.
For: New onset type I diabetesSweden · Belgium · Italy - Ongoing, recruitingTherapeutic exploratory (Phase II)
A 12-Month, Randomized, Controlled, Open-Label, Dose Escalation Study Evaluating Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of an Anti-CD2 Monoclonal Antibody, TCD601(siplizumab) Compared to Anti-Thymocyte Globulin (rATG), as Induction Therapy in de novo Renal Transplant Recipients
This study looks at a new medicine called TCD601 (siplizumab) for people who have recently had a kidney transplant. It compares TCD601 to a standard treatment to see if it's safe and how well it helps prevent the body from rejecting the new kidney.
For: Renal TransplantationSweden · Spain · Austria - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus Bevacizumab and FOLFIRI in Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)
This study looks at a new drug, magrolimab, combined with standard treatments for advanced bowel cancer that has spread and can't be operated on. It aims to see if this new combination is safe and helps people live longer without their cancer getting worse.
For: Metastatic Colorectal Cancer (mCRC)Germany · Spain · France